The 28th February 2018 will mark the eleventh international Rare Disease Day that is co-ordinated by EURORDIS. It is held annually on the last of February with the aim to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives.
1 in 20 people live with a rare disease at some point in their life, therefore it is important to create awareness of rare diseases improving the general public’s knowledge and encourage key decision makers and researchers to address the needs of those living with rare disease.
According to the European Union, a rare disease is defined as a condition that affects fewer than 1 in 2,000 people. Currently, there may be as many as 7,000 rare diseases. Researchers have made progress in learning how to diagnose, treat, and even prevent a variety of rare diseases.1 There is however, still much work to be done because most rare diseases have no treatments.
As a global diagnostic company Randox fully supports this campaign to increase and promote research that is dedicated to revolutionising healthcare for those with rare diseases. At Randox over 16% of turnover is reinvested in R&D, we therefore, have more new tests in development than any other diagnostic company.
Randox Biosciences offers an extensive portfolio of over 900 products, for a multitude of R&D applications including more than 500 monoclonal and polyclonal antibodies and over 140 human recombinant proteins as well as antibody fragment, buffers and diluents and plasma.
To meet precise requirements, Randox Biosciences offer customised antibody generation services to the pharmaceutical and biotechnology industry. Our custom development service, which encompasses antibodies and human recombinant proteins has achieved tremendous success within the biopharmaceuticals and diagnostic industries.
Our customisation service has proven incredibly successful in the research and development industries allowing access to our expertise to obtain the antibody and protein most relevant to your line of work. With over 300 highly trained research scientists and over 35 years’ experience in commercial assay development, Randox Biosciences can also provide a tailor made assay development service to meet your specifications In both a timely and cost-effective manner.
Our scientists have spent over £220 million researching the thousands of biomarkers present in our bodies and have identified the gold standard in testing. Our patented Biochip Array Technology is the world’s only diagnostic grade biochip. This state-of-the-art technology has revolutionised the diagnostics industry by offering a unique testing platform which allows multiple tests to be carried out from a single patient sample.
These products are manufactured at our ISO 13485 certified manufacturing plant in the United Kingdom using state of the art facilities and our product list continues to grow in line with customer requirements and Randox’s continuing diagnostic research.
This Rare Disease Day, we are urging the pubic to not only help raise awareness of rare diseases but also educate themselves on the impact they have on patient’s lives. As a global diagnostic company, Randox Biosciences is committed to the ongoing development of diagnostic tests, as well as research into numerous disease areas to improve health worldwide.
To find out more email us at firstname.lastname@example.org
Join the campaign with us on Twitter and LinkedIn with the official hashtag #RareDiseaseDay
1 – National Centre for Advancing Translational Sciences